NEW YORK (GenomeWeb News) – Sequenom shareholders this week filed suit against the company and several individual current and former executives in relation to the company's mishandling of data surrounding its non-invasive test for fetal gene and chromosome abnormalities.

The complaint, filed Monday in the US District Court for the Southern District of California, alleges breach of fiduciary duties against a number of current and ex-officials, and levels charges of insider stock trading against one of the former officials.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.